Prediction of Preeclampsia (PE) at 11-13 Week
Launched by CHIU YEE LIONA POON · Jun 3, 2018
Trial Information
Current as of September 16, 2025
Completed
Keywords
ClinConnect Summary
The investigators have previously constructed Bayes model in the first-trimester which combines maternal characteristics and medical history (Mat-CH) together with mean arterial pressure (MAP), uterine artery pulsatility index (PI), and serum placental growth factor (PlGF) with a plan to assess the predictive performance.
The reference standards will be PE defined according to the International Society for the Study of Hypertension in Pregnancy and the American College of Obstetricians and Gynecologists. The systolic blood pressure should be \>140 mm Hg and/or the diastolic blood pressure ...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Aged ≥ 18 years
- • Singleton pregnancy
- • Live fetus
- • Provide Informed and written consent in the official language of the country
- Exclusion Criteria:
- • Unable to provide written Informed consent learning difficulties or serious mental illness or an inability to understand spoken and written the official language of the country.
- • Multiple Pregnancy
- • Non-viable fetus (missed spontaneous abortion or stillbirth)
About Chiu Yee Liona Poon
Chiu Yee Liona Poon is a dedicated clinical trial sponsor committed to advancing medical research and enhancing patient care through innovative clinical studies. With a focus on ethical practices and rigorous scientific methodologies, Ms. Poon oversees a diverse portfolio of trials that aim to evaluate the safety and efficacy of novel therapeutics across various therapeutic areas. Her leadership is characterized by a collaborative approach, fostering partnerships with healthcare professionals, regulatory bodies, and research institutions to ensure the highest standards of quality and compliance are met throughout the research process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, Hong Kong
Bangkok, Thailand
Singapore, Singapore
Tokyo, Japan
Hong Kong, Hong Kong
Singapore, Singapore
Nanjing, China
Taipei, Taiwan
Kunming, China
Chennai, Tamil Nadu, India
Toyama, Toyama Prefecture, Japan
Osaka, Japan
Tokyo, Japan
Bangkok, Thailand
Patients applied
Trial Officials
Liona CY Poon
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials